Asset Details
Do you wish to reserve the book?
Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy
Do you wish to request the book?
Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy
2022
Overview
Cardiomyopathies have unresolved genotype–phenotype relationships and lack disease-specific treatments. Here we provide a framework to identify genotype-specific pathomechanisms and therapeutic targets to accelerate the development of precision medicine. We use human cardiac electromechanical in-silico modelling and simulation which we validate with experimental hiPSC-CM data and modelling in combination with clinical biomarkers. We select hypertrophic cardiomyopathy as a challenge for this approach and study genetic variations that mutate proteins of the thick (
MYH7
R403Q/+
) and thin filaments (
TNNT2
R92Q/+
,
TNNI3
R21C/+
) of the cardiac sarcomere. Using in-silico techniques we show that the destabilisation of myosin super relaxation observed in hiPSC-CMs drives disease in virtual cells and ventricles carrying the MYH7
R403Q/+
variant, and that secondary effects on thin filament activation are necessary to precipitate slowed relaxation of the cell and diastolic insufficiency in the chamber. In-silico modelling shows that Mavacamten corrects the MYH7
R403Q/+
phenotype in agreement with hiPSC-CM experiments. Our in-silico model predicts that the thin filament variants TNNT2
R92Q/+
and TNNI3
R21C/+
display altered calcium regulation as central pathomechanism, for which Mavacamten provides incomplete salvage, which we have corroborated in TNNT2
R92Q/+
and TNNI3
R21C/+
hiPSC-CMs. We define the ideal characteristics of a novel thin filament-targeting compound and show its efficacy in-silico. We demonstrate that hybrid human-based hiPSC-CM and in-silico studies accelerate pathomechanism discovery and classification testing, improving clinical interpretation of genetic variants, and directing rational therapeutic targeting and design.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
